Phoxilium® reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy

Background: Although associated with severe clinical complications, phosphate remains a neglected ion. Additionally, phosphate balance during continuous renal replacement therapy (CRRT) is complex and multifunctional. The present retrospective study investigated the effects of phosphate-containing CRRT fluid on phosphate homeostasis. Methods: We retrospectively analysed 112 patients treated with CRRT at Skane University Hospital, Sweden. The control group was treated with Hemosol (R) B0 (no phosphate; n = 36) as dialysis and replacement fluid, while the study group received Phoxilium (R) (phosphate; n = 76) as dialysis fluid and Hemosol (R) B0 as replacement fluid. Results: Hypophosphataemia (<0.7 mM) occurred in 15% of the treatment days in the control group compared with 7% in the study group (P = 0.027). Magnesium substitution was reduced by 40% in the study group (P < 0.001). No differences in acid-base parameters were detected between the groups. Conclusions: In this larger cohort, we could confirm that Phoxilium (R) reduced the episodes of hypophosphataemia during CRRT. A beneficial effect on magnesium balance could also be observed.